RUBEN PINERO FUENTES: Open Payments
NPI 1710326046 · EDINBURG, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$70,536 in 108 payments from 10 companies in 2025. Trend: 2023 $1,346 · 2024 $1,387 · 2025 $70,536
Speaker / faculty: $56,522Consulting: $6,200Travel & lodging: $5,514Food & beverage: $2,300
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 53 | $39,854 |
| Neurocrine BioSciences, Inc. | 25 | $30,009 |
| E.R. Squibb & Sons, L.L.C. | 9 | $223 |
| Alkermes, Inc. | 13 | $168 |
| Janssen Pharmaceuticals, Inc | 1 | $121 |
| Otsuka America Pharmaceutical, Inc. | 3 | $76 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| ABBVIE INC. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
Products named: UZEDY, INGREZZA, AUSTEDO XR, COBENFY, ARISTADA, INVEGA SUSTENNA, REXULTI, CAPLYTA.
Industry payments across TX — which companies pay providers there.
